Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases

Colorectal Cancer Clinical Trial

— PLANET  

Official title:

An Open Label Randomized, Multi-Centre Exploratory Phase II Study to Evaluate the Efficacy and Safety of the Combination of Panitumumab With FOLFOX 4 Chemotherapy or Panitumumab With FOLFIRI Chemotherapy in Subjects With Wild- Type KRAS Colorectal Cancer and Liver-only Metastases.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00885885
• Other study ID #: TTD-08-04
• Secondary ID: EudraCT: 2008-00
• Status: Completed
• Phase: Phase 2
• First received: April 21, 2009
• Last updated: July 31, 2017
• Start date: May 2009
• Est. completion date: March 2015

Study information

• Verified date: July 2017
• Source: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the efficacy and safety of the combination of Panitumumab with FOLFOX 4 Chemotherapy or Panitumumab with FOLFIRI Chemotherapy in Subjects with Wild- Type KRAS Colorectal Cancer and liver-only Metastases.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: March 2015
• Est. primary completion date: March 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Man or woman > 18 years < 75 of age

• Competent to comprehend, sign, and date an IEC-approved informed consent form

• Histologically confirmed adenocarcinoma of the colon or rectum

• Wild Type KRAS status

• Metastatic colorectal carcinoma exclusively affecting only the liver, compliant with one of the following criteria

1. Number of liver metastasis = 4.

2. Size of one liver metastasis > 10 cm in diameter.

3. Liver metastases technically not resectable.

• At least 1 uni-dimensionally measurable lesion

• Patients with the following characteristics will be included:

1. Recurrence after adjuvant treatment with 5-fluorouracil/folinic acid or capecitabine +/- radiotherapy with a disease-free interval > than 6 months after its completion; or after oxaliplatin containing adjuvant treatment with a disease-free interval > than 12 months

2. Recurrence after surgical treatment and/or radiotherapy with no adjuvant systemic treatment.

3. De novo diagnosis of the disease.

• Patients with simultaneous liver metastases are eligible, if the primary tumor has been resected at least 1 month prior chemotherapy.

• Prior radiotherapy is acceptable.

• Patients deemed to have no major contra-indication to liver surgery from a general health perspective.

• Karnofsky performance status = 70%

• Adequate bone marrow function: neutrophils = 1.5 x109/ L; platelets = 100 x109/ L;hemoglobin = 9g/ dL

• Hepatic and metabolic function as follows:

Total bilirubin count = 1.5 x ULN and not increasing more than 25% within the last 4 weeks; ALAT and ASAT < 5 x ULN;

• Renal function, calculated creatinine clearance or 24 hour creatinine clearance = 50 mL/ min.

• Magnesium > LLN

Exclusion Criteria:

• Prior anti-EGFr antibody therapy (eg, cetuximab) or treatment small molecule EGFr tyrosine kinase inhibitors (eg, erlotinib).Subjects who have experienced an infusion reaction to their first dose of anti-EGFR therapy (cetuximab) may participate in this clinical trial.

• Surgery (not including diagnostic biopsy) and/or radiotherapy in the 4 weeks prior to inclusion in the study.

• Metastasis on any site other than the liver, including extrahepatic lymph nodes.

• Prior malignant tumor in the last 5 years, except a history of basal cell carcinoma of the skin or pre-invasive carcinoma of the skin.

• Systemic chemotherapy, hormonal therapy, immunotherapy or experimental or approved proteins/antibodies (eg, bevacizumab) = 30 days before inclusion

• Unresolved toxicities from prior systemic therapy that, in the opinion of the investigator, does not qualify the patient for inclusion

• Significant cardiovascular disease including unstable angina or myocardial infarction within 6 months before initiating study treatment or a history of ventricular arrhythmia

• History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline chest CT scan

• Treatment for systemic infection within 14 days before initiating study treatment

• Active inflammatory bowel disease or other bowel disease causing chronic diarrhoea (defined as > 4 loose stools per day)

• History of Gilbert's syndrome or dihydropyrimidine deficiency

• History of any medical condition that may increase the risks associated with study participation or may interfere with the interpretation of the study results

• Known positive test for human immunodeficiency virus infection, hepatitis C virus, chronic active hepatitis B infection

• subject allergic to the ingredients of the study medication or to Staphylococcus protein A

• Any co-morbid disease that would increase risk of toxicity

• Any kind of disorder that compromises the ability of the subject to give written informed consent and/or comply with the study procedures

• Any investigational agent within 30 days before enrolment

• Must not have had a major surgical procedure within 28 days of randomization

• Subject who is pregnant or breast feeding

• Woman or man of childbearing potential not consenting to use adequate contraceptive precautions i.e. double barrier contraceptive methods (eg diaphragm plus condom), or abstinence during the course of the study and for 6 months after the last study drug administration for women, and 1 month for men

• Subject unwilling or unable to comply with study requirements

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Drug:
• Panitumumab+FOLFOX-4
Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes. A cycle of panitumumab is defined as 14 days. FOLFOX 4 chemotherapy will be administered on day 1 of each 14-day treatment cycle: Oxaliplatin 85mg/m2 as a 120 minute infusion on day 1 of each cycle Folinic acid 200mg/m2 as a 120 minute infusion on days 1 and 2 A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on days 1 and 2 5-FU at 600mg/m2 as a continuous infusion of 22 hour infusion on days 1 and 2
• Panitumumab+FOLFIRI
Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes. A cycle of panitumumab is defined as 14 days. FOLFIRI chemotherapy will be administered on day 1 of each 14-day treatment cycle: Irinotecan 180 mg/m2 will be administered over 90 minutes ± 15 minutes on day 1 of each cycle Folinic acid 400 mg/m2 will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on day 1 5-FU at 2400 mg/m2 continuous intravenous infusion over 46-hour ± 2-hour on day 1 of each cycle.

Locations

Country	Name	City	State
Spain	Spanish Cooperative Group for Gastrointestinal Tumour Therapy	Madrid

Sponsors (2)

Lead Sponsor	Collaborator
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)	Amgen

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response rate		2009-2013
Secondary	% of patients whose disease becomes resectable		2009-2013
Secondary	Time to resection		2009-2013
Secondary	Duration of response		2009-2013
Secondary	Progression-free survival		2009-2013
Secondary	Time to treatment failure		2009-2013
Secondary	Time to disease relapse following surgery.		2009-2013
Secondary	Adverse Events		2009-2013
Secondary	Evaluation of molecular predictive markers for response.		2009-2013

External Links

•   Link